Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis vs Laser in Diabetic Macular Edema
NCT00387582Phase 2Completed
- Sponsor
- Rocky Mountain Retina Consultants
- Start
- Jul 2006
- Primary completion
- Feb 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Rocky Mountain Retina Consultants. Primary endpoint: Prevention of vision loss as evidenced by ETDRS visual acuity at 12 months. Started Jul 2006; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00387582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387582.